Experimental HCV Drugs
Experimental HCV Drugs
4-Drug Oral Regimen Cures More than 90% of Chronic Hepatitis C Patients
- Details
- Category: HCV Treatment
- Published on Tuesday, 23 October 2012 00:00
- Written by Press Release
An all-oral, interferon-free combination regimen containing 3 experimental direct-acting hepatitis C virus (HCV) drugs from Abbott plus ribavirin produced sustained virological response in 99% of previously untreated people with genotype 1 chronic hepatitis C and 93% of patients who experienced prior failure of interferon-based therapy, according to preliminary data from the ongoing Aviator study.
Interferon-free HCV Treatment: Simeprevir and ALS-2200 Enter Phase 2 All-oral Studies
- Details
- Category: HCV Treatment
- Published on Wednesday, 26 September 2012 00:00
- Written by Press Release
A trio of interferon-free, all-oral regimens for treatment of chronic hepatitis C virus (HCV) are entering Phase 2 clinical trials, the intermediate stage of development after basic safety and antiviral activity have been established, according to recent press releases from Medivir and Vertex. 
Monoclonal Antibody May Help Prevent and Clear Hepatitis C Virus
- Details
- Category: HCV Treatment
- Published on Tuesday, 04 September 2012 00:00
- Written by Liz Highleyman
A human monoclonal antibody dubbed HCV1 was able to prevent exposed chimpanzees from becoming infected with hepatitis C virus, and chimps with acute and chronic infection experienced reductions in HCV viral load, according to a study published in the August 30, 2012, issue of the open-access journal PLoS Pathogens. 
ICAAC 2012: HCV Polymerase Inhibitor Sofosbuvir Appears Safe and Effective for HIV/HCV Coinfected People
- Details
- Category: HCV Treatment
- Published on Wednesday, 12 September 2012 00:00
- Written by Liz Highleyman
HIV/
HCV coinfected people taking the experimental hepatitis C virus (HCV) polymerase inhibitor sofosbuvir (formerly GS-7977) experienced a rapid decline in HCV viral load similar to that seen in HIV negative patients, researchers reported this week at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2012) in San Francisco. Side effects were also similar, and there was no sign of interactions with antiretroviral drugs in this 14-day study
Hepatitis C Candidate BMS-986094 Halted after Death, IDX19368 Gets Clinical Hold
- Details
- Category: HCV Treatment
- Published on Thursday, 30 August 2012 00:00
- Written by Bristol-Myers Squibb
Bristol-Myers Squibb (BMS) announced last week that it has discontinued development of its experimental hepatitis C virus (HCV) NS5B nucleotide polymerase inhibitor BMS-986094 (formerly known as INX-189) due to serious adverse events including 1 death. In related news, the Food and Drug Administration (FDA) placed a clinical hold on another drug in the same class -- Idenix's IDX19368 -- due to concerns about BMS-986094. 
More Articles...
- AIDS 2012: Adding Nitazoxanide Does Not Improve Interferon Cure Rate for HIV/HCV Coinfected Patients
- Early Biomarker Changes Predict Which Hepatitis C Patients Develop Severe Liver Disease
- Hepatitis C Polymerase Inhibitor BMS-986094 Suspended Due to Safety Concern
- Advocates Release Updated Report on Pipeline Drugs for HIV, Hepatitis C, and TB
Web Design and Development by